Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an update.
Hansoh Pharmaceutical Group announced that its innovative drug Ameile (Aumolertinib Mesilate Tablets) has received approval from the National Medical Products Administration of China for a new indication. This approval allows Ameile to be used as an adjuvant treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific genetic mutations. This marks the fourth indication approval for Ameile, enhancing its market positioning and expanding its treatment options for NSCLC.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on innovative drug development. The company specializes in creating treatments for non-small cell lung cancer (NSCLC) and has developed Ameile, a third-generation EGFR-TKI drug.
Average Trading Volume: 10,735,776
Technical Sentiment Signal: Buy
Current Market Cap: HK$141.5B
For an in-depth examination of 3692 stock, go to TipRanks’ Stock Analysis page.